AMARIN CORP PLC\UK Direct Operating Communications Costs
AMARIN CORP PLC\UK (AMRN) reported Direct Operating Communications Costs of $14.20 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-04-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DirectOperatingCommunicationsCosts · last filed 2021-04-29
- AMARIN CORP PLC\UK direct operating communications costs for the quarter ending 2021-03-31 was $14.20M.
| Period end | Direct Operating Communications Costs 0 month | Direct Operating Communications Costs 3 month |
|---|---|---|
| 2021-03-31 | $14.20M 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $7.30M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |